Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Alumis Inc. ( (ALMS) ) has shared an announcement.
On January 2, 2026, Alumis Inc. and its subsidiary Acelyrin issued a Notice of Material Breach and claim for indemnification to Climb Bio after Climb Bio failed to pay a $3 million development milestone that came due on January 1, 2026 under a 2024 asset purchase agreement related to the budoprutug program. The dispute escalated when Climb Bio, which had previously disclosed significant milestone and royalty obligations to Acelyrin tied to budoprutug, filed a declaratory judgment action on December 31, 2025 in Delaware asserting that budoprutug is not a “Product” under the agreement; Alumis contends this stance contradicts the contract and prior statements and says it will seek the unpaid milestone with interest, legal fees, and other relief, signaling a potentially protracted legal and financial conflict between the parties.
The most recent analyst rating on (ALMS) stock is a Hold with a $11.00 price target. To see the full list of analyst forecasts on Alumis Inc. stock, see the ALMS Stock Forecast page.
Spark’s Take on ALMS Stock
According to Spark, TipRanks’ AI Analyst, ALMS is a Neutral.
The score is held back primarily by very large losses and substantial ongoing cash burn, despite a healthier balance sheet with low leverage. Technicals are a meaningful positive, with price strength above key moving averages and supportive momentum. Valuation remains pressured because the company is unprofitable (negative P/E) and has no dividend support.
To see Spark’s full report on ALMS stock, click here.
More about Alumis Inc.
Alumis Inc., through its wholly owned subsidiary Acelyrin, operates in the biopharmaceutical sector, focusing on the development and commercialization of drug candidates such as budoprutug under asset purchase and licensing arrangements that provide for milestone payments, royalties on worldwide net sales, and sublicense income tied to the progress of licensed products.
Average Trading Volume: 1,007,857
Technical Sentiment Signal: Buy
Current Market Cap: $1.02B
For a thorough assessment of ALMS stock, go to TipRanks’ Stock Analysis page.